Interventional, Open Label, Reduced/Staged, Single Dose Study Investigating the Pharmacokinetic Properties of Lu AF35700 in Subjects With Renal Impairment and in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs LU AF-35700 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 26 Sep 2019 Status changed from recruiting to discontinued.
- 01 Mar 2019 Planned End Date changed from 8 Feb 2019 to 1 Feb 2020.
- 01 Mar 2019 Planned primary completion date changed from 8 Feb 2019 to 1 Feb 2020.